Gritstone Oncology initiated with a Buy at H.C. Wainwright. H.C. Wainwright analyst Swayampakula Ramakanth started Gritstone Oncology with a Buy rating and $17 price target. The company’s core technology is its Gritstone EDGE artificial intelligence platform, which has demonstrated an up to nine-fold increased prediction accuracy for identifying potential tumor neoantigens, Ramakanth tells investors in a research note. Further, Granite-001 has the potential to become the first “universal” vaccine that can be used across the full range of cancer indications, which could significantly increase its market potential, says the analyst.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.